“`html
FILSPARI® (sparsentan) Gains Prominence in Updated IgA Nephropathy Treatment Guidelines
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 – CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are acknowledging the recently published updates to the Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guidelines for the management of IgA Nephropathy (IgAN) and Immunoglobulin A vasculitis. These updated guidelines, a critical resource for nephrologists and other healthcare professionals, refine diagnostic criteria, treatment goals, and therapeutic approaches, potentially marking a significant shift in how IgAN, also known as Berger’s disease, is managed. IgAN, a leading cause of kidney failure globally, is characterized by the buildup of immunoglobulin A (IgA) in the kidneys, leading to impaired filtration and progressive kidney damage.
A key highlight of the 2025 guidelines is the emphasis on remission of proteinuria (
Notably, the guidelines address the role of FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA). The updated guidance suggests that FILSPARI may be an appropriate first-line treatment option for managing IgAN-induced nephron loss, particularly in contrast to the traditional RASi-first approach (Renin-Angiotensin System inhibitors). Moreover, the guidelines specify FILSPARI as the only therapy with proven efficacy demonstrated in clinical trials compared to optimized RASi therapy, citing the PROTECT trial, which enrolled a substantially larger patient cohort than previous RASi trials.
“The updated KDIGO guidance represents an important step forward for the IgA Nephropathy community,” said Prof. Dr. med. Jürgen Floege, Senior Professor, Div. Nephrology and Clinical Immunology at the University Hospital, RWTH Aachen, Germany. “For patients and clinicians, this provides greater clarity and confidence in navigating treatment decisions, with the ultimate goal of improving long-term kidney outcomes.”
“The new IgA Nephropathy management recommendations provide important guidance for clinicians treating this rare disease. The inclusion of FILSPARI in the KDIGO guidelines is a reflection of its benefit-risk profile and reinforces its role in helping eligible patients reduce proteinuria and slow kidney function loss, while being generally well-tolerated”, said Dr. Achim Obergfell, Global Medical Head Nephrology Portfolio CSL Vifor. “The updated KDIGO guidelines mark
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/9973.html
